Assessment of anti-arthritic activity of lipid matrix encased berberine in rheumatic animal model
The purpose of this study was to evaluate the drug delivery and therapeutic potential of berberine (Br) loaded nanoformulation in rheumatoid arthritis (RA)-induced animal model. The Br-loaded NLCs (nanostructured lipid carriers) were prepared employing melt-emulsification process, and optimised through Box-Behnken design. The prepared NLCs were assessed for in-vitro and in-vivo evaluations. The optimised NLCs exhibited a mean diameter of 180.2 ± 0.31 nm with 88.32 ± 2.43% entrapment efficiency. An enhanced anti-arthritic activity with reduced arthritic scores to 0.66 ± 0.51, reduction in ankle diameter to 5.80 ± 0.27 mm, decline in paw withdrawal timing, and improvements in walking behaviour were observed in the Br-NLCs treated group. The radiographic images revealed a reduction in bone and cartilage deformation. The Br-NLCs showed promising results in the management of RA disease, can be developed as an efficient delivery system at commercial levels, and may be explored for clinical application after suitable experiments in the future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Journal of microencapsulation - 40(2023), 4 vom: 13. Juni, Seite 263-278 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Singh, Neelu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0I8Y3P32UF |
|---|
| Anmerkungen: |
Date Completed 15.05.2023 Date Revised 15.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/02652048.2023.2194414 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354942964 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354942964 | ||
| 003 | DE-627 | ||
| 005 | 20231226063315.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/02652048.2023.2194414 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1183.xml |
| 035 | |a (DE-627)NLM354942964 | ||
| 035 | |a (NLM)36989347 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Singh, Neelu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Assessment of anti-arthritic activity of lipid matrix encased berberine in rheumatic animal model |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.05.2023 | ||
| 500 | |a Date Revised 15.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The purpose of this study was to evaluate the drug delivery and therapeutic potential of berberine (Br) loaded nanoformulation in rheumatoid arthritis (RA)-induced animal model. The Br-loaded NLCs (nanostructured lipid carriers) were prepared employing melt-emulsification process, and optimised through Box-Behnken design. The prepared NLCs were assessed for in-vitro and in-vivo evaluations. The optimised NLCs exhibited a mean diameter of 180.2 ± 0.31 nm with 88.32 ± 2.43% entrapment efficiency. An enhanced anti-arthritic activity with reduced arthritic scores to 0.66 ± 0.51, reduction in ankle diameter to 5.80 ± 0.27 mm, decline in paw withdrawal timing, and improvements in walking behaviour were observed in the Br-NLCs treated group. The radiographic images revealed a reduction in bone and cartilage deformation. The Br-NLCs showed promising results in the management of RA disease, can be developed as an efficient delivery system at commercial levels, and may be explored for clinical application after suitable experiments in the future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Berberine | |
| 650 | 4 | |a NLCs | |
| 650 | 4 | |a autoimmune | |
| 650 | 4 | |a complete Freund’s adjuvant | |
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Berberine |2 NLM | |
| 650 | 7 | |a 0I8Y3P32UF |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 700 | 1 | |a Pandey, Amit Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Pal, Ravi Raj |e verfasserin |4 aut | |
| 700 | 1 | |a Alka |e verfasserin |4 aut | |
| 700 | 1 | |a Parashar, Poonam |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Priya |e verfasserin |4 aut | |
| 700 | 1 | |a Mishra, Nidhi |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Dinesh |e verfasserin |4 aut | |
| 700 | 1 | |a Raj, Ritu |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Sukhveer |e verfasserin |4 aut | |
| 700 | 1 | |a Saraf, Shubhini A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of microencapsulation |d 1989 |g 40(2023), 4 vom: 13. Juni, Seite 263-278 |w (DE-627)NLM013098217 |x 1464-5246 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2023 |g number:4 |g day:13 |g month:06 |g pages:263-278 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/02652048.2023.2194414 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2023 |e 4 |b 13 |c 06 |h 263-278 | ||